White Paper

Fixing The Problem Of Representation In Clinical Research

Source: Trialbee AB
patient recruitment iStock-1299220556

The lack of demographic representation in clinical trials is long felt and a well-known challenge for the research community. In the United States, for example, many communities of patients are underrepresented. Whether these communities are defined by gender, race, ethnicity, or socioeconomic status, it is clear that their access to
clinical trials is insufficient.

Spurred on by the COVID-19 pandemic and the resulting need for a quickly produced, safe vaccine that would be effective for all people, the U.S. Food and Drug Administration (FDA) provided new guidance for industry around increasing the diversity of clinical trial populations and made clear that representation will an important factor in therapy approvals moving forward.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader